TheraRadar
← Back
Data updated: Jun 28, 2026

KNOA PHARMA

Big Pharma
Pharmaceuticals

KNOA PHARMA is a major pharmaceutical company with 6 FDA-approved products.

1987
Since
6
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
4 Small Molecules

KNOA PHARMA's Key Drugs

KNOA PHARMA's core commercial portfolio centers on ZURNAI (AUTOINJECTOR) — its most strategically important drugs approved in the last 15 years.

ZURNAI (AUTOINJECTOR)
CNS

Opioid Overdose

Approved 2024

KNOA PHARMA's Recent FDA Approvals

KNOA PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ZURNAI (AUTOINJECTOR) NDA
2024-08-07
nalmefene hydrochloride
Opioid Overdose

KNOA PHARMA's Therapeutic Areas

Disease areas where KNOA PHARMA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

KNOA PHARMA Pipeline Snapshot

Active clinical trials for KNOA PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ZURNAI (AUTOINJECTOR) leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling